JIANGSU JIBEIER PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.05 CNY | -1.33% |
|
+17.77% | -17.01% |
| Sales 2024 * | 1.08B 148M | Sales 2025 * | 1.33B 183M | Capitalization | 4.93B 680M |
|---|---|---|---|---|---|
| Net income 2024 * | 269M 37.12M | Net income 2025 * | 332M 45.82M | EV / Sales 2024 * | 4.58 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.71 x |
| P/E ratio 2024 * |
18.3
x | P/E ratio 2025 * |
14.8
x | Employees | 1,016 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 24.56% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.33% | ||
| 1 week | +17.77% | ||
| Current month | +6.67% | ||
| 1 month | +3.33% | ||
| 3 months | -1.70% | ||
| 6 months | +3.09% | ||
| Current year | -17.01% |
1 week
21.81
26.69
1 month
21.6026.69
Current year
17.4932.41
1 year
17.4941.96
3 years
14.9841.96
5 years
14.9854.97
10 years
14.9854.97
| Managers | Title | Age | Since |
|---|---|---|---|
Zhong yi Geng
CEO | Chief Executive Officer | 61 | 01-11-12 |
Suo Fu Zhao
DFI | Director of Finance/CFO | 57 | 17-05-07 |
Zheng Wang
CHM | Chairman | 47 | 01-11-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guo Xiang Yang
BRD | Director/Board Member | 72 | 18-05-09 |
Zhu Yun Xie
BRD | Director/Board Member | 49 | 18-05-09 |
Zhong yi Geng
CEO | Chief Executive Officer | 61 | 01-11-12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 26.05 | -1.33% | 2,496,321 |
| 24-04-25 | 26.4 | +5.05% | 3,044,990 |
| 24-04-24 | 25.13 | +1.29% | 2,132,363 |
| 24-04-23 | 24.81 | +7.26% | 2,400,746 |
| 24-04-22 | 23.13 | +4.57% | 1,493,093 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Jiangsu Jibeier Pharmaceutical Co Ltd is a company engaged in the research, development, production and sales of drugs. The Company's products are comprised of tablets, capsules and eye drops. The tablet products include Leucogen tablets, Nitrendipine and Atenolol tablets, Aceclofenac Enteric-coated tablets and Asarone tablets. The Company's products are used to improve white blood cells, treat high blood pressure, eye infections and other diseases.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
26.05
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.01% | 680M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- 688566 Stock
